Climb Bio Inc (NASDAQ:CLYM) — Market Cap & Net Worth
Market Cap & Net Worth: Climb Bio Inc (CLYM)
Climb Bio Inc (NASDAQ:CLYM) has a market capitalization of $425.61 Million ($425.61 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13376 globally and #3060 in its home market, demonstrating a -1.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Climb Bio Inc's stock price $8.91 by its total outstanding shares 47767980 (47.77 Million). Analyse CLYM operating cash flow to see how efficiently the company converts income to cash.
Climb Bio Inc Market Cap History: 2021 to 2026
Climb Bio Inc's market capitalization history from 2021 to 2026. Data shows change from $499.65 Million to $425.61 Million (-11.53% CAGR).
Index Memberships
Climb Bio Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #346 of 976 |
Weight: Climb Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Climb Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Climb Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CLYM by Market Capitalization
Companies near Climb Bio Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Climb Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Climb Bio Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Climb Bio Inc's market cap moved from $499.65 Million to $ 425.61 Million, with a yearly change of -11.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $425.61 Million | +122.75% |
| 2025 | $191.07 Million | +122.22% |
| 2024 | $85.98 Million | -33.33% |
| 2023 | $128.97 Million | -26.43% |
| 2022 | $175.31 Million | -64.91% |
| 2021 | $499.65 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Climb Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $425.61 Million USD |
| MoneyControl | $425.61 Million USD |
| MarketWatch | $425.61 Million USD |
| marketcap.company | $425.61 Million USD |
| Reuters | $425.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more